This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
The results are presented for the clopidogrel group versus the placebo group.
The rates of composite outcome measure were 9.3% and 11.4%, respectively, (p<0.0001).
The rates of all-cause death were 5.8% and 6.2%, respectively, (p=0.2779).
The rates of MI were 5.2% and 6.7%, respectively, (p=0.0004).
The rates of stroke were 1.2% and 1. 4%, respectively, (p=0.3532) .
The rates of bleeding were 3.70% and 2.70%, respectively, (p=0.0015).
The rates of major bleeding were 1.5% and 0.9%, respectively, (p=0.002).
The rates of life-threatening bleeding were 2.1% and 1.7%, respectively, (p=0.10).
The rates of major plus life-threatening bleeding were 0.1% and 0.1%, respectively, (p=1.00).
The rates of minor bleeding were 5.1% and 2.4%, respectively, (p<0.0001).
Clinical conclusions
The effectiveness analysis showed that clopidogrel was associated with fewer fatal and nonfatal cardiovascular events, especially due to the reduction in MIs. However, significantly more major and minor bleeding episodes were observed in clopidogrel-treated patients.
Measure of benefits used in the economic analysis
The summary benefit measure used was life expectancy. This was estimated from two independent sources, the Framingham Heart Study and the Saskatchewan Health database. These sources provided gender-and age-specific estimates of life years lost due to events, which were then applied to the CURE trial patient population. Mean survival beyond the end of the trial was estimated by integrating the survival curves, adjusted for various patient characteristics, including experience of specific subsequent ischaemic events. For patients who experienced multiple events of different types during the trial, lost life expectancy was estimated assuming a hierarchy of death, stroke and MI. It was further assumed that clopidogrel would be stopped at the end of the trial, thus there would be no reduction (or increase) in nonfatal events between the two arms. An annual discount rate of 3% was applied to future life-years gained (LYG).
Direct costs
The perspective of the third-party payer appears to have been used. The economic evaluation included the costs for hospitalisations (including diagnostic tests, therapeutic procedures and medications) and the cost of clopidogrel. Ambulatory care, including outpatient diagnostic procedures and testing, was not recorded and was thus excluded from the current analysis. Similarly, the use of medication other than the study drugs was not included because it was comparable across the patient groups. Non-cardiovascular follow-up hospitalisations were not considered because of their negligible impact on the total costs. The quantities of resources used were provided and the costs were presented as macro-categories for most items.
Resource use was estimated from data derived from the CURE trial. Each hospitalisation was assigned a diagnosisrelated group (DRG), as used in Medicare programmes in the USA, by coders who were blinded to the treatment group.
The costs for each DRG were estimated using average Medicare reimbursement rates. Such rates were obtained from the Medicare Part A data file and average private payer reimbursement rates derived from the MEDSTAT database. Consequently, a blended MEDSTAT-Medicare cost estimate was generated by applying MEDSTAT costs to patients in the CURE trial who were younger than 65 years and Medicare costs to those older than 65 years. The authors noted that MEDSTAT estimates included professional costs, which for Medicare were calculated as a percentage of the hospital costs by DRG. The costs beyond the trial period were estimated as the average per capita participant Medicare reimbursement. The price year was not reported. Some costs were incurred after the first year and were appropriately discounted at an annual rate of 3%.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not included in the economic evaluation.
Currency
US dollars ($).
Sensitivity analysis
A bootstrap method was used to estimate 95% confidence intervals (CIs) for both the costs and LYG. Univariate sensitivity analyses were also carried out to examine the robustness of the base-case cost-effectiveness ratios to variations in life expectancy (reduction of 50% or 80%), costs (addition of costs associated with bleeding or those due to prolonged life expectancy) and quality-adjusted survival. The authors chose the alternative values used.
Estimated benefits used in the economic analysis
The LYG with clopidogrel over placebo were 0.0699 (95% CI: -0.0077 -0.1440) when using the Framingham estimates and 0.0682 (95% CI: 0.0122 -0.1190) when using Saskatchewan estimates. The difference was mainly due to the reduction in the risk of death and stroke with clopidogrel.
Cost results
In-trial costs exclusive of clopidogrel were comparable between the groups, irrespective of the source of the costs.
When clopidogrel costs were included, in-trial costs were $13,019 with clopidogrel and $12,578 with placebo (difference $442, 95% CI: 62 -820) when using Medicare rates. The in-trial costs were $17,924 (clopidogrel) and
